DISCUSSION
ASYMPTOMATIC SARS-COV-2 INFECTION, MAY, REACTOGENICITY
A third (booster) BNT162b2 10-µg dose administered approximately 6 months after the second dose to 5- to 11-year olds increases neutralizing titers against SARS-CoV-2, including against Omicron BA.1 and BA.4/BA.5 strains, and is expected to confer protection against COVID-19 including illness caused by Omicron variants. This is in the context of previously observed immunogenicity and efficacy results across adolescent and adult clinical trial populations and from real-world data, which have collectively shown that a third (booster) dose of BNT162b2 substantially increases the magnitude and breadth of neutralization and provides protection against symptomatic SARS-CoV-2 infection, including those caused by Omicron variants [A third (booster) BNT162b2 10-µg dose administered to 5- to 11-year olds had an acceptable safety and tolerability profile, and no new safety concerns were identified. Reactogenicity after the third (booster) dose was mostly mild to moderate in severity, short-lived, and generally comparable to that observed after the two-dose series [Limitations of this analysis include the short follow-up, lack of efficacy assessment, and data in children who had a longer interval between the primary series and dose 3 were not available. Long-term follow-up from this and other studies is ongoing.These data contribute to evidence supporting benefits of a third (booster) BNT162b2 dose, which received emergency use authorization for 5- to 11-year olds in May 2022 [